Positive Interim Data from Trial for BonyPid Antibiotic Eluting Bone Substitute

Interim results from study of BonyPid®-1000 bone substitute in the treatment of open tibial fractures indicate that the product met performance and safety endpoints in first patients at 6 months.

Recruitment Status for ALLOB Delayed-Union Study

Bone Therapeutics completed recruitment of 16 patients in the Phase I/IIA delayed-union fracture study of ALLOB® allogeneic cell therapy product.

Bioactive Glass Shown Effective Towards Antibiotic-resistant Bacteria

Studies of BonAlive® indicate that the naturally-antibacterial bioactive glass yields excellent results in the treatment of osteomyelitis, without the use of local antibiotics.